PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31610190-0	2019	The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4+ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T+ Itpr3tf/J mice.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	37-45	inositol 1,4,5-triphosphate receptor 3	Mus musculus	178-183
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	interleukin 1 beta	Mus musculus	71-79
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	interleukin 6	Mus musculus	81-85
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	tumor necrosis factor	Mus musculus	87-96
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	interferon gamma	Mus musculus	98-107
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	113-122
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	123-126
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	interleukin 10	Mus musculus	153-158
26877948-3	2014	GIT27 (4,5-dihydro-3-phenyl-5-isoxasole acetic acid) is an active immunomodulatory agent that primarily targets macrophages and inhibits secretion of tumor necrosis factor alpha [as well as interleukin (IL)-1beta, IL-10, and interferon gamma].	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	0-5	tumor necrosis factor	Mus musculus	150-177
26877948-3	2014	GIT27 (4,5-dihydro-3-phenyl-5-isoxasole acetic acid) is an active immunomodulatory agent that primarily targets macrophages and inhibits secretion of tumor necrosis factor alpha [as well as interleukin (IL)-1beta, IL-10, and interferon gamma].	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	0-5	interleukin 10	Mus musculus	214-219
18460348-0	2008	Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	37-87	tumor protein p53	Homo sapiens	120-123